Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage.

ABSTRACT

Pneumococcal conjugate vaccines (PCV) may reduce nasopharyngeal carriage (NPC) of Streptococcus pneumoniae vaccine strains (VT), but serotype replacement with non-vaccine strains (NVT) has been reported. Bacterial NPC after PHiD-CV vaccination was assessed in the second year of life. Open descriptive study of NPC reported for 414 subjects vaccinated at 3-5 and 12-15 months of age with PHiD-CV with or without prophylactic paracetamol (PP) compared to 336 age-matched PCV-naïve controls. Carriage was assessed prior to and 1, 3, 7 and 12 months after PHiD-CV booster or MenACWY-TT control vaccination at 12-15 months of age. At each visit, carriage of VT was reduced by 22-35% in PHiD-CV recipients. Vaccine efficacy across all visits was 21.7% [95% CI 2.6; 37.0] (26.8% carriage in the PHiD-CV group versus 34.2% in controls). Carriage rates of NVT tended to be higher in PHiD-CV recipients. Pre-booster, these findings were more pronounced when PP had not been administered. No substantial effect of PHiD-CV vaccination was observed on NPC of other bacterial pathogens including non-typeable Haemophilus influenzae. Primary and booster vaccination with PHiD-CV reduced NPC of VT in the second year of life and tended to slightly increase that of NVT in line with previous experience with the 7-valent PCV.